Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone
Progression‐free survival · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to lower progression‐free survival (PFS) compared with chemotherapy (low certainty).
1 finding from 1 review
- Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without… 2021 · Cochrane Headline outcomes onlyHR 0.68 [0.51, 0.88]5 studies · 1886 participantsLow